A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through February 22, 2010.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA's product candidates includepimavanserin in Phase III for Parkinson's disease psychosis incollaboration with Biovail, a product candidate in Phase II for chronicpain and a product candidate in Phase I for glaucoma, both incollaboration with Allergan, and AM-831 in IND-track development incollaboration with Meiji Seika Kaisha. All of the product candidates inACADIA's pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871